Journal article · 2025 · Open access
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
The Lancet Oncology, 27(1), 23–35 · Published 23 December 2025 · DOI 10.1016/s1470-2045(25)00612-6
In brief
“Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial” is a 2025 journal article by Anne Sophie V M van den Heerik and 29 co-authors, published in The Lancet Oncology. OpenAlex counts 80 citations as of 17 November 2026, which puts it in the top 7% of works published in 2025 by citations. It is open access: the full text is free to read at Pure Amsterdam UMC.
- Citations
- 80
- Most cited in
- 2026 (78)
- Field-weighted impact
- 67.77
- References
- 31
- Authors
- 30
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
van den Heerik, A. S. V. M., Horeweg, N., Haverkort, M. A., Kuijsters, N., Kommoss, S., Koppe, F. L., Nowee, M. E., Westerveld, H. G., de Jong, M. A., Frühauf, F., Cnossen, J. S., Mens, J. W., Beukema, J. C., Chargari, C., Gillham, C., Jurgenliemk-Schulz, I. M., Vandecasteele, K., Hamann, M. F., Kiderlen, M., . . . Creutzberg, C. L. (2025). Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. The Lancet Oncology, 27(1), 23–35. https://doi.org/10.1016/s1470-2045(25)00612-6
MLA 9
van den Heerik, Anne Sophie V M, et al. “Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.” The Lancet Oncology, vol. 27, no. 1, 2025, pp. 23–35. https://doi.org/10.1016/s1470-2045(25)00612-6.
Chicago
van den Heerik, Anne Sophie V M, Nanda Horeweg, Marie A.D. Haverkort, Nienke Kuijsters, S Kommoss, Friederike L.A. Koppe, Marlies E. Nowee, et al. 2025. “Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.” The Lancet Oncology 27 (1): 23–35. https://doi.org/10.1016/s1470-2045(25)00612-6.
Harvard
van den Heerik, A. S. V. M. et al. (2025) ‘Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial’, The Lancet Oncology, 27(1), pp. 23–35. doi:10.1016/s1470-2045(25)00612-6.
IEEE
A. S. V. M. van den Heerik et al., “Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial,” The Lancet Oncology, vol. 27, no. 1, pp. 23–35, 2025, doi: 10.1016/s1470-2045(25)00612-6.
BibTeX
@article{vandenheerik2025molecular,
title = {{Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial}},
author = {van den Heerik, Anne Sophie V M and Horeweg, Nanda and Haverkort, Marie A.D. and Kuijsters, Nienke and Kommoss, S and Koppe, Friederike L.A. and Nowee, Marlies E. and Westerveld, Henrike G. and de Jong, Maria A.A. and Frühauf, Filip and Cnossen, Jeltsje S. and Mens, Jan Willem and Beukema, Jannet C. and Chargari, Cyrus and Gillham, Charles and Jurgenliemk-Schulz, Ina Maria and Vandecasteele, Katrien and Hamann, Moritz Franz and Kiderlen, Mandy and Staebler, Annette and Nijman, Hans W. and Wortman, Bastiaan G. and Asteinidou, Elefteria and de Boer, Stephanie M. and van den Hout, Wilbert B. and Verhoeven-Adema, Karen W. and Nout, Remi A. and Putter, Hein and Bosse, Tjalling and Creutzberg, Carien L.},
journal = {The Lancet Oncology},
year = {2025},
volume = {27},
number = {1},
pages = {23--35},
doi = {10.1016/s1470-2045(25)00612-6},
url = {https://doi.org/10.1016/s1470-2045(25)00612-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- endometrial cancer
- adjuvant therapy
- high-intermediate risk
- non-inferiority
- vaginal brachytherapy
- pelvic radiotherapy
- POLE mutation
- mismatch repair deficiency
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
van den Heerik, A. S. V. M., Horeweg, N., Haverkort, M. A., Kuijsters, N., Kommoss, S., Koppe, F. L., Nowee, M. E., Westerveld, H. G., de Jong, M. A., Frühauf, F., Cnossen, J. S., Mens, J. W., Beukema, J. C., Chargari, C., Gillham, C., Jurgenliemk-Schulz, I. M., Vandecasteele, K., Hamann, M. F., Kiderlen, M., . . . Creutzberg, C. L. (2025). Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. The Lancet Oncology, 27(1), 23–35. https://doi.org/10.1016/s1470-2045(25)00612-6
How many times has this paper been cited?
80 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Pure Amsterdam UMC: sign in and open the full text from this page.
Who wrote this paper?
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A.D. Haverkort, Nienke Kuijsters, S Kommoss, Friederike L.A. Koppe, Marlies E. Nowee, Henrike G. Westerveld, Maria A.A. de Jong, Filip Frühauf, Jeltsje S. Cnossen, Jan Willem Mens and 18 more.
What is the DOI of this paper?
10.1016/s1470-2045(25)00612-6, permanently at https://doi.org/10.1016/s1470-2045(25)00612-6. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.